Shaw-Min Hou

Shaw-Min Hou


Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Verified
Journal Article
Open access
PDF file
CCChi-Li Chung
Chi-Li Chung
JCJui-Hsuan Chen
Jui-Hsuan Chen
WHWei-Chieh Huang
Wei-Chieh Huang
Joen-Rong SheuJoen-Rong Sheu
Joen-Rong Sheu
CHChih-Wei Hsia
Chih-Wei Hsia
SHShaw-Min Hou
Shaw-Min Hou
Platelets are crucial for hemostasis and arterial thrombosis, which may lead to severe cardiovascular diseases (CVDs). Thus, therapeutic agents must be developed to prevent pathological platelet activation. Glabridin, a major bioalkaloid extracted from licorice root, improves metabolic abnormalities (i.e., obesity and diabetes) and protects against CVDs and neuronal disorders. To the best of our knowledge, no studies have focused on glabridin’s effects on platelet activation. Therefore, we investigated these effects in humans and mice. Glabridin exhibited the highest inhibitory effects on collagen-stimulated platelet aggregation and moderate effects on arachidonic-acid-stimulated activation; however, no effects were observed for any other agonists (e.g., thrombin or U46619). Glabridin evidently reduced P-selectin expression, ATP release, and intracellular Ca2+ ([Ca2+]i) mobilization and thromboxane A2 formation; it further reduced the activation of phospholipase C (PLC)γ2/protein kinase C (PKC), phosphoinositide 3-kinase (PI3K)/Akt/glycogen synthase kinase-3β (GSK3β), mitogen-activated protein kinase (MAPK), and NF-κB. In mice, glabridin reduced the mortality rate caused by acute pulmonary thromboembolism without altering bleeding time. Thus, glabridin effectively inhibits the PLCγ2/PKC cascade and prevents the activation of the PI3K/Akt/GSK3β and MAPK pathways; this leads to a reduction in [Ca2+]i mobilization, which eventually inhibits platelet aggregation. Therefore, glabridin may be a promising therapeutic agent for thromboembolic disorders.

12 January 2022 in Molecules
Verified
Journal Article
Open access
PDF file
WHWei-Chieh Huang
Wei-Chieh Huang
SHShaw-Min Hou
Shaw-Min Hou
MWMing-Ping Wu
Ming-Ping Wu
CHChih-Wei Hsia
Chih-Wei Hsia
Jayakumar ThanasekaranJayakumar Thanasekaran
Jayakumar Thanasekaran
Joen-Rong SheuJoen-Rong Sheu
Joen-Rong Sheu
Platelets play a critical role in arterial thrombosis. Rutaecarpine (RUT) was purified from Tetradium ruticarpum, a well-known Chinese medicine. This study examined the relative activity of RUT with NF-κB inhibitors in human platelets. BAY11-7082 (an inhibitor of IκB kinase [IKK]), Ro106-9920 (an inhibitor of proteasomes), and RUT concentration-dependently (1–6 μM) inhibited platelet aggregation and P-selectin expression. RUT was found to have a similar effect to that of BAY11-7082; however, it exhibits more effectiveness than Ro106-9920. RUT suppresses the NF-κB pathway as it inhibits IKK, IκBα, and p65 phosphorylation and reverses IκBα degradation in activated platelets. This study also investigated the role of p38 and NF-κB in cell signaling events and found that SB203580 (an inhibitor of p38) markedly reduced p38, IKK, and p65 phosphorylation and reversed IκBα degradation as well as p65 activation in a confocal microscope, whereas BAY11-7082 had no effects in p38 phosphorylation. The 2,2-diphenyl-1-picrylhydrazyl (DPPH) assay shows that RUT and BAY11-7082 did not exhibit free radical scavenging activity. In the in vivo study, compared with BAY11-7082, RUT more effectively reduced mortality in adenosine diphosphate (ADP)-induced acute pulmonary thromboembolism without affecting the bleeding time. In conclusion, a distinctive pathway of p38-mediated NF-κB activation may involve RUT-mediated antiplatelet activation, and RUT could act as a strong prophylactic or therapeutic drug for cardiovascular diseases.

24 January 2025 in Biomolecules
Verified
Journal Article
Open access
PDF file
SHShaw-Min Hou
Shaw-Min Hou
CYChun-Ming Yang
Chun-Ming Yang
WHWei-Chieh Huang
Wei-Chieh Huang
SCSsu-wei Cheng
Ssu-wei Cheng
Ting-lin YenTing-lin Yen
Ting-lin Yen
CHChih-Hsuan Hsia
Chih-Hsuan Hsia
Inflammation, a fundamental response to infection and injury, involves interactions among immune cells and signaling molecules. Dysregulated inflammation contributes to diseases such as autoimmune disorders and cancer. Interleukin-1 beta (IL-1β), produced by macrophages in response to lipoteichoic acid (LTA) from Gram-positive bacteria, is a key inflammatory mediator. Glabridin (GBD), a bioactive compound from licorice root, exhibits anti-inflammatory properties. This study investigates GBD’s effects on LTA-induced proinflammatory signaling in RAW 264.7 murine macrophages and alveolar macrophages, MH-S, focusing on IL-1β expression and signaling pathways. Cell viability assays confirmed that 20 μM GBD was non-cytotoxic. Confocal microscopy and quantitative PCR showed that GBD significantly reduced IL-1β fluorescence intensity, mRNA, and protein levels. GBD also inhibited inducible nitric oxide synthase (iNOS) expression and nitric oxide (NO) production. Further analysis revealed that GBD suppressed NF-κB p65 nuclear translocation and selectively modulated MAPK pathway activation by reducing JNK and p38 MAPK phosphorylation without affecting ERK. Studies using specific inhibitors demonstrated that IL-1β production reduction was mechanistically linked to MAPK pathway inhibition. These findings highlight GBD’s potential as a therapeutic agent for inflammatory diseases through its ability to modulate critical inflammatory mediators and signaling pathways.

21 September 2023 in Heliyon
Verified
Journal Article
Open access
YCYi Chang
Yi Chang
CHChih-Wei Hsia
Chih-Wei Hsia
WHWei-Chieh Huang
Wei-Chieh Huang
TJThanasekaran Jayakumar
Thanasekaran Jayakumar
CHChih-Hsuan Hsia
Chih-Hsuan Hsia
SHShaw-Min Hou
Shaw-Min Hou
Platelets play a vital role in the formation of dangerous arterial thrombosis. Platelets are activated by adhesive proteins or soluble agonists through their specific receptors. The receptor-mediated signaling pathways lead to common signaling events, which result in shape changes and inside–out signaling, leading fibrinogen binding to glycoprotein IIb/IIIa complex (integrin αIIbβ3). This interaction initiates integrin αIIbβ3-mediated outside-in signaling, subsequently culminating in granule secretion and aggregation. Myricetin is a flavonoid that occurs in a variety of plants. Although myricetin has been demonstrated to have several bioactive properties, its role in platelet activation has not been extensively studied. The present study demonstrated the ability of myricetin to inhibit platelet aggregation stimulated by collagen, thrombin, and U46619. Myricetin reduced the ATP-release, cytosolic Ca2+ mobilization, and P-selectin expression and the activation of PLCγ2/PKC, PI3K/Akt/GSK3β, and MAPK. Myricetin exerted a direct inhibitory effect on the activation of integrin αIIbβ3 by disrupting the binding between FITC-PAC-1 and the integrin. Moreover, myricetin suppressed integrin αIIbβ3-mediated outside–in signaling, such as integrin β3, Src, and Syk phosphorylation on immobilized fibrinogen. In animal studies, myricetin significantly prolonged the occlusion time of thrombotic platelet plug formation in mesenteric microvessels without extending bleeding time. This study concludes that myricetin is a natural integrin αIIbβ3 inhibitor and a novel antithrombotic agent.

9 March 2026 in Journal of Cellular Physiology
Verified
Journal Article
Open access
PDF file
JSJoen‐Rong Sheu
Joen‐Rong Sheu
WHWei‐Chieh Huang
Wei‐Chieh Huang
CCChao‐Chien Chang
Chao‐Chien Chang
CHChih‐Wei Hsia
Chih‐Wei Hsia
CHChih‐Hsuan Hsia
Chih‐Hsuan Hsia
SHShaw-Min Hou
Shaw-Min Hou
Platelets, as anucleate blood cells, play a pivotal role in the pathogenesis of cardiovascular diseases (CVDs), making antiplatelet therapy essential for preventing thrombotic events such as myocardial infarction. Thromboxane A₂ (TXA₂) is a key pro‐aggregatory mediator that drives platelet activation. Phosphorylation of vasodilator‐stimulated phosphoprotein (VASP) at Ser157 and Ser239 serves as a marker of cyclic nucleotide‐mediated inhibitory signaling. The crosstalk between TXA₂ signaling and site‐specific VASP phosphorylation in arachidonic acid (AA)‐stimulated human platelets remains unclear and requires further investigation. In this study, AA at 60 µM induced maximal platelet activation, as evidenced by ultrastructural changes and increased P‐selectin expression. Picotamide, a thromboxane synthase (TXS) inhibitor, effectively reversed AA‐induced alterations, including ultrastructural remodeling, P‐selectin expression, TXA₂ production, adenosine triphosphate (ATP)‐release, mobilization of [Ca²⁺]ᵢ, and integrin α IIb β 3 activation. Importantly, picotamide's inhibition of platelet aggregation was unaffected by adenylate or guanylate cyclase inhibitors, suggesting a mechanism independent of cyclic nucleotide signaling. AA selectively increased VASP phosphorylation at Ser239, but not Ser157. While picotamide alone had no effect, its sequential administration with AA significantly enhanced Ser157 phosphorylation without altering Ser239 levels. These findings suggest that AA differentially regulates VASP phosphorylation sites via distinct mechanisms: Ser239 via a TXA₂‐independent pathway associated with inhibitory signaling, and Ser157 via a TXA₂‐dependent pathway linked to platelet activation. Finally, picotamide demonstrated superior antithrombotic efficacy compared to aspirin at an equivalent dose, as evidenced by real‐time intravital imaging of thrombotic platelet plug formation in vivo. These results highlight TXS inhibition as a promising strategy for modulating platelet activation and thrombosis.